Status:
UNKNOWN
NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Surgical resection is the best treatment option for colorectal cancer. Despite this radical approach, recurrences within five years are still common. Several authors have proposed that the immunosuppr...
Eligibility Criteria
Inclusion
- Patients admitted for resection of colorectal cancer under laparoscopic surgery
- American Society of Anesthesiologists class I-III.
- The subject is able to understand the study objectives, the experimental protocol and procedures, and is capable of providing an informed consent.
Exclusion
- Subjects allergic to any of the study drugs.
- BMI \> 35 kg/m2.
- Severe renal or hepatic failure.
- Pregnancy.
- Emergent procedure.
- Heart failure NYHA \> III.
- Systolic blood pressure \< 90 mmHg.
- Advanced heart block (unless patient has a pacemaker).
- Unstable angina and/or myocardial infarction within past 6 weeks.
- FEV1 ≤ 0.8 L.
- Oxygen-dependent patient.
- Electrocardiographic abnormalities
- Treatment with immunosupressive drugs, corticosteroids, NSAIDS, antiarythmic
- Morphine intolerance or allergy
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01841294
Start Date
January 1 2012
End Date
December 1 2013
Last Update
April 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada, H1T 2M4